Latest News about ABBV
Recent news which mentions ABBV
AbbVie shares jump as results beat expectations despite blockbuster Humira’s declining sales
July 27, 2023
From MarketWatch
US Stocks Buckle Up For Solid Open On Meta's Earnings Boost, Fed Relief — But Analyst Advises Some 'Value-Style' Rebalancing
July 27, 2023
From Benzinga
AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis
July 26, 2023
From Benzinga
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
July 26, 2023
From Benzinga
3 Stocks to Buy While They Are on Sale
July 26, 2023
From Motley Fool
From Motley Fool
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
July 25, 2023
From Benzinga
From Benzinga
AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition
July 25, 2023
From MarketWatch
From InvestorPlace
Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility
July 21, 2023
From Benzinga
3 High-Yield Dividend Stocks I Plan on Holding Forever
July 21, 2023
From Motley Fool
From InvestorPlace
7 Fantastic Forever Stocks for Long-Term Lucrative Gains
July 20, 2023
From InvestorPlace
3 Biotech Stocks for Getting Rich in 2023
July 18, 2023
From InvestorPlace
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
July 17, 2023
From Benzinga
From Benzinga
3 Dividend Growth Stocks to Buy and Hold
July 16, 2023
From Motley Fool
7 Spectacular High-Yield Dividend Stocks to Buy in July
July 16, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.